TY - JOUR
T1 - Rating scales for cognition in Huntington's disease
T2 - Critique and recommendations
AU - Mestre, Tiago A.
AU - Bachoud-Lévi, Anne Catherine
AU - Marinus, Johan
AU - Stout, Julie C.
AU - Paulsen, Jane S.
AU - Como, Peter
AU - Duff, Kevin
AU - Sampaio, Cristina
AU - Goetz, Christopher G.
AU - Cubo, Esther
AU - Stebbins, Glenn T.
AU - Martinez-Martin, Pablo
AU - the Members of the MDS Committee on Rating Scales Development
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum. As part of the International Parkinson's Disease and Movement Disorder Society-sponsored project to review all clinical rating scales used in Huntington's disease, a systematic review of the literature was performed to identify cognitive scales used in Huntington's disease and make recommendations for their use. A total of 17 cognitive scales were identified and evaluated. None of the scales met criteria for a “recommended” status. For assessing severity of cognitive dysfunction, the Montreal Cognitive Assessment was “recommended with caveats.” The UHDRS Cognitive Assessment, the UHDRS-For Advanced Patients cognitive section, the Alzheimer's Disease Assessment Scale-Cognitive Subscale, the Frontal Assessment Battery, the Mattis Dementia Rating Scale, the Mini-Mental State Examination, and the Repeatable Battery for the Assessment of Neuropsychological Status were “suggested” for evaluating severity of cognitive impairment. The MoCA was “suggested” as a screening tool for cognitive impairment. The major challenge in the assessment of cognition in Huntington's disease is the lack of a formal definition of dementia and/or mild cognitive impairment in this disease. The committee concluded that there is a need to further validate currently available cognitive scales in Huntington's disease, but that it is premature to recommend the development of new scales. Recently developed Huntington's disease-specific scales, such as the Huntington's Disease-Cognitive Assessment Battery, hold promise but require the completion of more comprehensive clinimetric development.
AB - Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum. As part of the International Parkinson's Disease and Movement Disorder Society-sponsored project to review all clinical rating scales used in Huntington's disease, a systematic review of the literature was performed to identify cognitive scales used in Huntington's disease and make recommendations for their use. A total of 17 cognitive scales were identified and evaluated. None of the scales met criteria for a “recommended” status. For assessing severity of cognitive dysfunction, the Montreal Cognitive Assessment was “recommended with caveats.” The UHDRS Cognitive Assessment, the UHDRS-For Advanced Patients cognitive section, the Alzheimer's Disease Assessment Scale-Cognitive Subscale, the Frontal Assessment Battery, the Mattis Dementia Rating Scale, the Mini-Mental State Examination, and the Repeatable Battery for the Assessment of Neuropsychological Status were “suggested” for evaluating severity of cognitive impairment. The MoCA was “suggested” as a screening tool for cognitive impairment. The major challenge in the assessment of cognition in Huntington's disease is the lack of a formal definition of dementia and/or mild cognitive impairment in this disease. The committee concluded that there is a need to further validate currently available cognitive scales in Huntington's disease, but that it is premature to recommend the development of new scales. Recently developed Huntington's disease-specific scales, such as the Huntington's Disease-Cognitive Assessment Battery, hold promise but require the completion of more comprehensive clinimetric development.
KW - clinimetrics
KW - cognition
KW - Huntington's disease
KW - rating scales
KW - validation
UR - http://www.scopus.com/inward/record.url?scp=85039156724&partnerID=8YFLogxK
U2 - 10.1002/mds.27227
DO - 10.1002/mds.27227
M3 - Review Article
AN - SCOPUS:85039156724
SN - 0885-3185
VL - 33
SP - 187
EP - 195
JO - Movement Disorders
JF - Movement Disorders
IS - 2
ER -